Login to Your Account

Annexon seeks answers in complement-mediated neurodegeneration with $44M series B

By Marie Powers
News Editor

Thursday, June 23, 2016

Armed with a $44 million series B, Annexon Biosciences Inc. extended the development runway for its still-preclinical lead asset through completion of phase II programs designed to answer key questions about its pursuit of classical complement pathway inhibitors to treat neurodegenerative disorders.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription